Abstract:
Diffuse large B-cell lymphoma (DLBCL) is a highly invasive malignant lymphoma, and the molecular mechanism of its pathogenesis is not fully understood. Next generation sequencing (NGS) is an increasingly mature gene assay technology, which has been widely applied in recent years to study the genetics of DLBCL. Targeted therapy development has progressed significantly on the basis of these studies, which has made genetic mutations in DLBCL become the new research hotspot. This review summarizes the progress in research on progress-related gene mutations in DLBCL.